Open AccessPredicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures
Author(s) -
Enrique Álvarez,
Laura Piccio,
Robert Mikesell,
Kathryn Trinkaus,
Becky Parks,
Robert T. Naismith,
Anne H. Cross
Publication year - 2015
Publication title -
multiple sclerosis journal - experimental translational and clinical
Language(s) - English
Resource type - Journals
ISSN - 2055-2173
DOI - 10.1177/2055217315623800
Subject(s) - rituximab , medicine , multiple sclerosis , cerebrospinal fluid , magnetic resonance imaging , cxcl13 , immunology , gastroenterology , pathology , inflammation , antibody , chemokine , radiology , chemokine receptor
Multiple sclerosis patients with optimal response to rituximab had higher cerebrospinal fluid IgG and CXCL13 indices, more gadolinium-enhancing lesions, and less disability at baseline. Rituximab treatment led to decreased markers of inflammation and tissue damage. If validated, these results will help identify multiple sclerosis patients who will respond optimally to B-cell depletion.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom